Communiqués Rakovina Therapeutics Inc. OTC Markets

Actions

RKVTF

CA75103L3092

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 18:58:05 05/10/2026			Varia. 5j.	Varia. 1 janv.
0,1925 ^USD	+9,31%		+4,22%	+152,96%

01/10	Rakovina Therapeutics Inc. s’associe à Celvion Therapeutics pour tirer parti de l’intelligence artificielle (IA) et des données cliniques en vie réelle dans le développement de médicaments anticancéreux de précision	CI
17/09	Rakovina Therapeutics Inc. annonce la nomination du Dr Ranjit Bindra au sein de son conseil scientifique consultatif	CI

Communiqués

01/10	Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development	AQ
17/09	Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member	AQ
10/09	Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors	AQ
01/09	Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update	AQ
31/08	Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement	AQ
19/08	Rakovina Therapeutics Announces Results from 2026 Annual General Meeting	AQ
12/08	Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement	AQ
15/07	Rakovina Therapeutics Announces $1.5 Million Private Placement	AQ
01/06	Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update	AQ
30/04	Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update	AQ
22/04	Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting	AQ
23/03	Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 – World’s Premier Cancer Research Forum	AQ
12/03	Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement	AQ
06/03	Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements	AQ
21/02	Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million	AQ
04/02	Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit	AQ
27/01	Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring	AQ
08/01	Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors	AQ
17/12	Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California	AQ
10/12	Rakovina Therapeutics Announces Upcoming Webinar with Variational AI	AQ
01/12	Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update	AQ
29/11	Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program	AQ
24/11	Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting	AQ
24/11	Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting	AQ
18/11	Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit	AQ